Tempus Reports Third Quarter 2026 Results

Tempus AI, Inc. (TEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempus Reports Third Quarter 2026 Results CHICAGO, November 2, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026. “Q3 was anot

Event · Earnings
Also in this documentGuidance · raise · $1.6B–$1.61B

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 2, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TEM
Bullish
high confidence
Mentioned
$TEM
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TEMBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to attract short‑term buying, while the pending Personalis acquisition adds a near‑term execution risk.

02

Market read

Earnings beat and raised guidance provide a fresh catalyst for TEM, likely driving short‑term price appreciation.

03

What to watch

Potential integration challenges with new Merck/Moderna and BMS deals; pending Personalis acquisition could add dilution.

Relevance 8/10Novelty 9/10Timing: pre‑market today
AlphAI · Earnings readTEM · Third Quarter 2026 · ended September 30, 2026

Tempus Reports Third Quarter 2026 Results

✓Strong quarter

Third-quarter revenue increased 23%, Data and Applications grew 33%, gross profit increased 27%, and Adjusted EBITDA rose to $25.6 million from $1.5 million. The company increased full-year revenue guidance to $1.60 to $1.605 billion while maintaining expected full-year Adjusted EBITDA of ~$65 million.

Revenue
$412M
23 % y/y
Diagnostics, three months ended September 30, 2026
$303M
20% y/y
Gross margin · GAAP
64.8 %
EPS · non-GAAP
$ 0.07
164 % y/y
Full year 2026 outlook
$1.60 to $1.605 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total net revenue, three months ended September 30, 2026GAAP$411.5M–23 %
Gross profit, three months ended September 30, 2026GAAP$266.7M–27 %
Gross margin, three months ended September 30, 2026GAAP64.8 %––
Non-GAAP gross profit, three months ended September 30, 2026non-GAAP$271.2M––
Non-GAAP gross margin, three months ended September 30, 2026non-GAAP65.9 %––
Technology research and development expense, three months ended September 30, 2026GAAP$45.71M––
Research and development expense, three months ended September 30, 2026GAAP$ 46,000––
Selling, general and administrative expense, three months ended September 30, 2026GAAP$231.9M––
Operating expenses, three months ended September 30, 2026GAAP$323.6M––
Non-GAAP operating expenses, three months ended September 30, 2026non-GAAP$256.8M––
Loss from operations, three months ended September 30, 2026GAAP−$56.86M–7 %
Non-GAAP income (loss) from operations, three months ended September 30, 2026non-GAAP$14.42M–267 %
Net loss, three months ended September 30, 2026GAAP−$14.85M–81 %
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.08 )–83 %
Non-GAAP net income (loss), three months ended September 30, 2026non-GAAP$13.36M–168 %
Non-GAAP net income (loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP$ 0.07–164 %
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$25.57M–1,633 %
Total net revenue, nine months ended September 30, 2026GAAP$1.14B––
Gross profit, nine months ended September 30, 2026GAAP$735.2M––
Gross margin, nine months ended September 30, 2026GAAP64.4 %––
Loss from operations, nine months ended September 30, 2026GAAP−$217.5M––
Non-GAAP income (loss) from operations, nine months ended September 30, 2026non-GAAP$134K––
Net loss, nine months ended September 30, 2026GAAP−$135.1M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (0.75 )––
Non-GAAP net income (loss), nine months ended September 30, 2026non-GAAP−$16.98M––
Non-GAAP net income (loss) per share, basic and diluted, nine months ended September 30, 2026non-GAAP$ (0.09 )––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$30.78M––
Net cash used in operating activities, nine months ended September 30, 2026GAAP−$71.59M––
Purchases of property and equipment, nine months ended September 30, 2026GAAP−$23.66M––
Net cash used in investing activities, nine months ended September 30, 2026GAAP−$38.68M––
Net cash provided by financing activities, nine months ended September 30, 2026GAAP$96.14M––

Segments

SegmentRevenueq/qy/y
Diagnostics, three months ended September 30, 2026Driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%.$303.5M–20%
Data and applications, three months ended September 30, 2026Insights grew 29%.$108.1M–33%
Diagnostics, nine months ended September 30, 2026No segment driver was provided for the nine-month period.$853.9M––
Data and applications, nine months ended September 30, 2026No segment driver was provided for the nine-month period.$288.2M––

Full year 2026 outlook

  • Revenue$1.60 to $1.605 billion
  • Note~25% annual growth
  • NoteAdjusted EBITDA of ~$65 million

What drove it

  • Oncology volume growth accelerated to 32%.
  • Minimal Residual Disease volume was ~12,000 tests, up 300%.
  • Data and Applications revenue increased 33%, with Insights increasing 29%.
  • Growth in Data and Applications led gross-profit growth.
  • In October, Tempus announced a BMS collaboration that brought total data licensing bookings to >$550 million year to date.
  • Tempus directly licensed oncology data and models to BMS for up to $137.5 million over a five-year term, while BMS and Pathos licensed Alzheimer’s or dementia data for $55 million over a five-year term.

Concerns

  • The company recorded a GAAP net loss of $ (14,851 ) in the third quarter and $ (135,128 ) for the nine months ended September 30, 2026.
  • GAAP operating expenses were $ 323,565 in the third quarter, including $ 231,857 of selling, general and administrative expense.
  • Third-quarter net loss included $50.8 million of stock-based compensation expense and related employer payroll taxes.
  • The company had convertible promissory note of 175,967 and convertible senior notes, net, of 1,174,877 at September 30, 2026.
  • The pending Personalis acquisition remained subject to shareholder approval, with the shareholder meeting planned for November 30, 2026.

What to watch

  • Execution against full-year 2026 revenue guidance of $1.60 to $1.605 billion and expected Adjusted EBITDA of ~$65 million.
  • Sustainability of 32% Oncology volume growth, ~12,000 MRD test volume, and 33% Data and Applications revenue growth.
  • Commercialization and data-licensing activity under the BMS, Merck, and Moderna collaborations.
  • The planned November 30, 2026 Personalis shareholder vote and the potential completion of the acquisition.
  • Progress toward building a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years.

Balance sheet and cash flow

  • Cash and cash equivalents at September 30, 2026: $ 590,479.
  • Marketable equity securities at September 30, 2026: $ 46,874 current and $ 212,276 less current portion.
  • Cash and marketable securities at quarter end: $854.4 million.
  • Convertible promissory note at September 30, 2026: 175,967.
  • Convertible senior notes, net, at September 30, 2026: 1,174,877.
  • Revolving credit facility at September 30, 2026: —.
  • Long-term debt, net, at September 30, 2026: —.
  • Net decrease in cash, cash equivalents and restricted cash for the nine months ended September 30, 2026: $ (14,217 ).
  • Proceeds from convertible senior notes, net of initial purchasers' discount, for the nine months ended September 30, 2026: 443,132.
  • Principal payments on long-term debt for the nine months ended September 30, 2026: (207,717 ).
  • Principal payments on revolving credit facility for the nine months ended September 30, 2026: (100,000 ).

Analysis

Tempus reported third-quarter GAAP revenue of $ 411,537, up 23 % from $ 334,206. Diagnostics generated $ 303,470, with 20% growth driven by Oncology volume growth of 32%, partly offset by Hereditary revenue growth of 3%. Data and applications generated $ 108,067 and grew 33%, while Insights grew 29%. MRD volume was ~12,000 tests, up 300%.

Gross profit rose 27 % to $ 266,701, and GAAP gross margin increased to 64.8 % from 62.8 %. Both major businesses expanded gross margin: Diagnostics gross margin was 62.4 % versus 61.0 %, and Data and applications gross margin was 71.5 % versus 68.5 %. The faster growth of Data and Applications and its higher reported gross margin were central to the gross-profit improvement.

GAAP loss from operations was $ (56,864 ), compared with $ (60,996 ). GAAP operating expenses were $ 323,565, including $ 231,857 of selling, general and administrative expense. On a non-GAAP basis, income from operations was $ 14,422 compared with a loss of $ (8,662 ), and Adjusted EBITDA was $ 25,572 compared with $ 1,476. The GAAP net loss narrowed to $ (14,851 ) from $ (79,982 ), while non-GAAP net income was $ 13,359. The third-quarter net loss included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities.

For the nine months ended September 30, 2026, total net revenue was $ 1,142,139 and Adjusted EBITDA was $ 30,783. Net cash used in operating activities improved to $ (71,586 ) from $ (181,302 ). At September 30, 2026, cash and cash equivalents were $ 590,479, while marketable equity securities were $ 46,874 current and $ 212,276 less current portion. The balance sheet also reported convertible promissory note of 175,967 and convertible senior notes, net, of 1,174,877.

Management increased full-year 2026 revenue guidance to $1.60 to $1.605 billion, representing ~25% annual growth, and continued to expect Adjusted EBITDA of ~$65 million. Commercial activity included the October BMS collaboration, which management said brought total data licensing bookings to >$550 million year to date, as well as a Merck and Moderna collaboration supporting potential commercialization of intismeran autogene. Regulatory review cleared for the pending Personalis acquisition, whose shareholder meeting is planned for November 30, 2026.

Management, verbatim

Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications.

Eric Lefkofsky, founder and CEO of Tempus

Not in the filing

stated, not guessed
  • Prior-quarter comparisons were not reported for the presented operating metrics.
  • Free cash flow was not reported.
  • Quarterly operating cash flow was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Prior guidance was not provided, so comparison with prior guidance is unavailable.
  • Guidance for gross margin, operating expenses, and tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Tempus AI filed an 8‑K announcing Q3 earnings and updated guidance, including new strategic collaborations with Merck, Moderna and BMS.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 2026 results with revenue up 23% to $411.5M and raised full‑year revenue guidance to $1.60‑$1.605B.

Expected impact

likely upward as market prices in higher revenue outlook

Evidence & confidence

Revenue beat and raised guidance signal improved growth trajectory, prompting buying interest.

Market effects

Positive data may boost sentiment in AI‑enabled healthcare and precision‑medicine sector.

U.S. biotech/tech stocks could see modest gains.

Limited to investors focused on AI health platforms.

Counterpoint

Guidance raise may already be priced in; execution risk on new collaborations could temper upside.

Key entities

  • Tempus AI, Inc.

    AI‑driven precision‑medicine platform reporting Q3 results.

  • Merck & Co.

    Strategic collaborator on individualized neoantigen therapy.

  • Moderna

    Co‑developer of neoantigen therapy with Tempus.

  • BMS

    Licensing agreement for oncology data and models.

Every TEM earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.